We found that, in the case of pancreatic cancer also, treatment with EHMT2 inhibitors (A366 and UNC0642) resulted in increased NK cell-mediated cytotoxicity (Fig. 6C), AZGP1 upregulation, and TGF-β1 downregulation (Fig. 6D). Here, EHMT2 is linked to familial pancreatic carcinoma.